Prise en charge des sténoses et
thromboses de l’Artère
Fémorale superficielle
Recommandations TASC II
nom année type patients 1an 2ans 3ans 5ans
green 2000 prothese 240 78 44/68
klinkert 2003 prothese 76 52/57
veine 75 76/80
Johnson
WC
2001 veine 226 81a 73a
HUV 261 70a 53a
prothese 265 69 39a
Archie
JP Jr.
1994 veine 232 87 81
prothese 62 54 48
NOM patients lesion occlusi
on
stenose stent 6 12 24 36
stanley
1996
176 200 45 58 58 46 38
cejna
1999
176 70 27 43 33 79/86 a 72/70 a
soder
2000
60 188 67 121 0 48
schneider
2000
318 411 411 0 82/82 33/65
jamsen
2002
173 218 120 98 2 37 31
bequemin
2003
227 227 50 177 nitinol 92/96 a 89/93 a 82/80 a
baril
2008
125 149 58.9 47.9
Schillin
ger
2006
104 nitinol 55
NOM patients lesion occlusi
on
stenose stent 6 12 24 36 48
Bouffi
2013
58 SIA 77/90 70/90 64/90
Superb
2012
264 266 60 206 nitinol 78.5
Resilient
2010
134 153 41 112 nitinol 72.2
Durability
II
2013
287 287 40 247 nitinol 67.7
Complete
SFA
2012
196 213 nitinol 73.1
SUPER
2012
150 150 140 10 nitinol 42.6 /4
6 b
VIBRANT
2013
148 Viabahn 25.9/24b
78/89a
VIPER
2013
113 119 67 52 viabahn 73/92
Mc Quade
2010
50 nitinol 72 63 63 59
Traitement endovasculaire :
réinterventions
Paclitaxel-Coated Versus Uncoated Balloon Angioplasty Reduces Target Lesion Revascularization in Patients With Femoropopliteal Arterial Disease: A
Meta-Analysis of Randomized Trials Salvatore Cassese
Traitement endovasculaire :
réinterventions
Paclitaxel-Coated Versus Uncoated Balloon Angioplasty Reduces Target Lesion Revascularization in Patients With Femoropopliteal Arterial Disease: A
Meta-Analysis of Randomized Trials Salvatore Cassese
morbi-mortalité

Stenose fem sup

  • 1.
    Prise en chargedes sténoses et thromboses de l’Artère Fémorale superficielle
  • 2.
  • 3.
    nom année typepatients 1an 2ans 3ans 5ans green 2000 prothese 240 78 44/68 klinkert 2003 prothese 76 52/57 veine 75 76/80 Johnson WC 2001 veine 226 81a 73a HUV 261 70a 53a prothese 265 69 39a Archie JP Jr. 1994 veine 232 87 81 prothese 62 54 48
  • 4.
    NOM patients lesionocclusi on stenose stent 6 12 24 36 stanley 1996 176 200 45 58 58 46 38 cejna 1999 176 70 27 43 33 79/86 a 72/70 a soder 2000 60 188 67 121 0 48 schneider 2000 318 411 411 0 82/82 33/65 jamsen 2002 173 218 120 98 2 37 31 bequemin 2003 227 227 50 177 nitinol 92/96 a 89/93 a 82/80 a baril 2008 125 149 58.9 47.9 Schillin ger 2006 104 nitinol 55
  • 5.
    NOM patients lesionocclusi on stenose stent 6 12 24 36 48 Bouffi 2013 58 SIA 77/90 70/90 64/90 Superb 2012 264 266 60 206 nitinol 78.5 Resilient 2010 134 153 41 112 nitinol 72.2 Durability II 2013 287 287 40 247 nitinol 67.7 Complete SFA 2012 196 213 nitinol 73.1 SUPER 2012 150 150 140 10 nitinol 42.6 /4 6 b VIBRANT 2013 148 Viabahn 25.9/24b 78/89a VIPER 2013 113 119 67 52 viabahn 73/92 Mc Quade 2010 50 nitinol 72 63 63 59
  • 6.
    Traitement endovasculaire : réinterventions Paclitaxel-CoatedVersus Uncoated Balloon Angioplasty Reduces Target Lesion Revascularization in Patients With Femoropopliteal Arterial Disease: A Meta-Analysis of Randomized Trials Salvatore Cassese
  • 7.
    Traitement endovasculaire : réinterventions Paclitaxel-CoatedVersus Uncoated Balloon Angioplasty Reduces Target Lesion Revascularization in Patients With Femoropopliteal Arterial Disease: A Meta-Analysis of Randomized Trials Salvatore Cassese
  • 8.